CompoAtlas

循立通軟膠囊

循立通軟膠囊 : Product registered in Taiwan. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

TFDA, Taiwan tablets, capsules and medical nutrition registers, retrieved 27 October 2026.

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

No point flagged by the rules applied to recognised ingredients.

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
HAWTHORN EXTRACT (CRATAEGUS OXYACANTHA L.)HAWTHORN EXTRACT (CRATAEGUS OXYACANTHA L.)Not identified
L-ARGININEL-ARGININENot identified
GRAPE EXTRACTGRAPE EXTRACTNot identified
FENUGREEK EXTRACTFENUGREEK EXTRACTNot identified
CURCUMA LONGA L. EXTRACTCURCUMA LONGA L. EXTRACTNot identified
CO-ENZYME Q10CO-ENZYME Q10Ubiquinone
SWINE GELATINSWINE GELATINNot identified
SOYBEAN OILSOYBEAN OILNot identified
SOY LECITHINSOY LECITHINNot identified
CALCIUM CARBONATECALCIUM CARBONATECalcium
GLYCEROLGLYCEROLGlycérol
ALLURA RED ACALLURA RED ACNot identified
PURIFIED WATERPURIFIED WATERNot identified
BRILLIANT BLUE FCFBRILLIANT BLUE FCFNot identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Product record

Registration number
1139050170
Chinese name
循立通軟膠囊
English name
SUN LE PONG SOFTGEL
Type
Imported tablets and capsules
Published status
Status not provided in this export; the validity date is shown separately
Licence holder
百郡企業有限公司
Registration date
2024-08-15
Published validity end
2029-08-15

Original register data

View published fields and their variants
Product name
循立通軟膠囊
Active ingredients
HAWTHORN EXTRACT (CRATAEGUS OXYACANTHA L.);;L-ARGININE;;GRAPE EXTRACT;;FENUGREEK EXTRACT;;CURCUMA LONGA L. EXTRACT;;CO-ENZYME Q10;;SWINE GELATIN;;SOYBEAN OIL;;SOY LECITHIN;;CALCIUM CARBONATE;;GLYCEROL;;ALLURA RED AC;;PURIFIED WATER;;BRILLIANT BLUE FCF;;
Valid until
1180815
Registration number
1139050170
Licence holder
百郡企業有限公司
Registration date
1130815
Published reference
DHC0B390501703
Published English name
SUN LE PONG SOFTGEL

Official source

View the official register, number 1139050170

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • CO-ENZYME Q10
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Sources cited by Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line